60 Degrees Pharmaceuticals
SXTP
8 hedge funds and large institutions have $615K invested in 60 Degrees Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
81% more capital invested
Capital invested by funds: $340K → $615K (+$275K)
14.65% more ownership
Funds ownership: 18.37% → 33.03% (+15%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kathmere Capital Management
Wayne,
Pennsylvania
|
+$194K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$28.4K |
| 4 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$24.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.81K |
| 3 |
Barclays
London,
United Kingdom
|
-$1.29K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$88 |
| 5 |
TPWA
Twin Peaks Wealth Advisors
Burlingame,
California
|
-$14 |
SXTP Hedge Fund Activity: Q2 2026 in Review
8 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in 60 Degrees Pharmaceuticals (SXTP) for Q2 2026, worth a combined $615K — up 81% from $340K a quarter earlier.
Fund positioning in SXTP was balanced in Q2 2026: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Kathmere Capital Management, adding an estimated $194K. The largest seller was UBS Group, cutting an estimated $28.7K.
- 8 institutional investors held 60 Degrees Pharmaceuticals (SXTP) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $615K of 60 Degrees Pharmaceuticals stock for Q2 2026, up 81% quarter-over-quarter.
- 3 funds opened new 60 Degrees Pharmaceuticals positions in Q2 2026 and 3 closed out, a net change of 0 holders.
- The largest 60 Degrees Pharmaceuticals buyer in Q2 2026 was Kathmere Capital Management, an estimated $194K added.
- The largest 60 Degrees Pharmaceuticals seller in Q2 2026 was UBS Group, an estimated $28.7K sold.
Based on aggregated 13F filings for Q2 2026.